Tel: 7209011789 N. K. MITTAL & ASSOCIATES sss: CHARTERED ACCOUNTANTS iri Plaza, Opp Andheri Railway Station, Near Mc Donald's, Andheri (West ndassociates@gmacom /akm@akmital com /ca_mittalgereditimacom = Websit N. K. Mittal B.Com, FCA, LLB, EMBA ‘Mumbai - 400 058, www.nkmittal.com LIMITED REVIEW REPORT FOR THE PERIOD ENDED 30.06.2015 We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 30™ June, 2015 except for the disclosures regarding ‘Public Shareholding’ and ‘Promoter and Promoter Group Shareholding’ which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not ‘express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards! and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement. For N. K. MITTAL & ASSOCIATES: Chartered Accountants: Wael N.K.MITTAL_ (Proprietor) M.No.46785, Place: Mumbai Date: 08.08.2015Se ee ose] sper| seneve| sosose ine] wr] wor] ee] son) a0 some] sro] spe — sase| se | -vom| spl sez] wats ee er : vase] asa] sansa ns sax] ee] aes] as 8 —are| ft ooo] 2]T]RESTOR COMPLANTS an oe sae2015 eee (Freee sig esti Rarseing wei the ene gue 11 Te ebove resus havo boon fevawod ye Aust Commies and approved by ta Bead of Drecr ats meting ld on 08.08.2015. 2 ourine te quarter Marsa Phama i, heouph ts whl owned sbsidary Marsias Pham Me, as scaled 10% share al Tne Cp Larson Ie, Ne Yo Tee Cap iorstorie fort lent mecfatcer ond irate sf Ue generic parce eliniing CTC ond pm pesto as emanates eer SO usue plod tam t's US EDA approved oily in Faring, New York. Tine Cep Labratatas cise ero debt compary. Tins seatepe aun il hip Mansars to eand fe marutacuang ans mane capaiter ts the US markt, 8 The Consoleted Financial Statements include Financial Slatemets che subsidiaries Nova Pharmaceuticals Ausalasia Py Ld and Maksans Pharma (UK) Linked '5 The Company's primal engapd ina single business segment cf Martacing & Make of Pamaceucsl Formulas. © The nou oro quar ended Match 3.2018 ae he batanengTeucebetweon auld ues fapsct ofthe Wl rancal year endee arch 31,2085 anno enaustnépublshes yeortn eto gue uote December 1.204 bain the at te en of he ak aur of the Sc year 7 Preous yee ues have teen gioupee cantid uhetavar nesta, £9.39 aks thm comparable wih te cunt yar fae Fer! oo SALDANHA, ‘Managing Directo.